New breakthrough in developing more personalized treatments for lung cancer
Distinct responses of lung adenocarcinoma and squamous cell carcinoma to anti‑angiogenic therapy are primarily determined by differences in their tumor microenvironments.
This study reports that distinct responses of lung adenocarcinoma and squamous cell carcinoma to anti‑angiogenic therapy are primarily determined by differences in their tumor microenvironments, particularly the role of fibroblasts. Adenocarcinoma shows more active angiogenesis and higher oxygenation linked to fibroblast‑driven synergy between VEGF and TIMP‑1, whereas squamous carcinoma has inefficient angiogenesis and greater hypoxia. These findings suggest that patient selection for anti‑angiogenic and immunotherapy combinations should be guided by microenvironmental and angiogenic biomarkers such as TIMP‑1, enabling more personalized and effective therapeutic strategies.
The differential tumor microenvironment explains why anti‑angiogenic therapies are effective in lung adenocarcinoma but not in squamous cell carcinoma, highlighting the need to tailor treatment strategies based on sub‑type and microenvironmental biomarkers. This could improve patient outcomes by selecting therapies that target the specific angiogenic and hypoxic pathways active in each cancer subtype.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability